Why was this study done? Juvenile dermatomyositis (JDM) is the most common type of idiopathic inflammatory myopathy in childhood, and most patients have a chronic disease course requiring prolonged administration of systemic glucocorticoids and immunosuppressive agents. The initial management for patients with moderately severe JDM is relatively standardized, typically including methotrexate and systemic glucocorticoids with…
A phase 2 clinical trial has demonstrated the effectiveness for multiple doses of subcutaneous sonelokimab for the treatment of adults with active psoriatic arthritis.
Burmester et al. characterized the long-term safety profile of upadacitinib treatment across multiple rheumatic diseases.
Two new treatment studies among patients with systemic lupus erythematosus and lupus nephritis had promising results.
Summaries of selected research abstracts on ANCA-associated vasculitis & IgA vasculitis from the International Vasculitis Workshop.Â
In a study, all doses of LEVI-04 demonstrated significant pain relief for patients with knee osteoarthritis compared with placebo.
The FDA accepted a new drug application for suzetrigine, a non-opioid analgesic, based on the results from clinical trials in patients with neuropathy and those post-surgery.
Figueroa-Parra et al. set out to evaluate the effect of glucocorticoid regimens on renal response, infections and mortality rates among patients with lupus nephritis (LN). The researchers analyzed the control arms of randomized clinical trials and found a higher exposure to glucocorticoids during the initial treatment of LN was associated with better renal outcomes, at the cost of increased infections and mortality.
Upadacitinib, as a tablet and oral solution, is now FDA approved to treat children age 2 years and older with active polyarticular juvenile idiopathic arthritis or psoriatic arthritis.
Lupus Fog? By Laura C. Plantinga, PhD, Patricia P. Katz, PhD, S. Sam Lim, MD, MPH, C. Barrett Bowling, MD, MSPH, & Jinoos Yazdany, MD, MPH Why was this study done? Perceived cognitive impairment (i.e., lupus fog) is common in systemic lupus erythematosus (SLE). However, comprehensive, multidomain assessments of objective cognitive function are rarely performed….